PAVmed Cost Of Revenue from 2010 to 2024

PAVMZ Stock  USD 0.01  0.01  40.94%   
PAVmed Series Cost Of Revenue yearly trend continues to be fairly stable with very little volatility. Cost Of Revenue is likely to outpace its year average in 2024. During the period from 2010 to 2024, PAVmed Series Cost Of Revenue regression line of annual values had r-squared of  0.50 and arithmetic mean of  1,168,351. View All Fundamentals
 
Cost Of Revenue  
First Reported
2010-12-31
Previous Quarter
6.4 M
Current Value
6.7 M
Quarterly Volatility
2.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check PAVmed Series financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PAVmed Series' main balance sheet or income statement drivers, such as Interest Expense of 559.5 K, Selling General Administrative of 32.5 M or Other Operating Expenses of 74.8 M, as well as many indicators such as Price To Sales Ratio of 11.54, Dividend Yield of 3.0E-4 or Days Sales Outstanding of 14.05. PAVmed financial statements analysis is a perfect complement when working with PAVmed Series Valuation or Volatility modules.
  
Check out the analysis of PAVmed Series Correlation against competitors.

Latest PAVmed Series' Cost Of Revenue Growth Pattern

Below is the plot of the Cost Of Revenue of PAVmed Series Z over the last few years. Cost of Revenue is found on PAVmed Series Z income statement and represents the costs associated with goods and services PAVmed Series provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is PAVmed Series' Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PAVmed Series' overall financial position and show how it may be relating to other accounts over time.
Cost Of Revenue10 Years Trend
Slightly volatile
   Cost Of Revenue   
       Timeline  

PAVmed Cost Of Revenue Regression Statistics

Arithmetic Mean1,168,351
Geometric Mean61,697
Coefficient Of Variation204.07
Mean Deviation1,769,326
Median14,226
Standard Deviation2,384,288
Sample Variance5.7T
Range6.7M
R-Value0.71
Mean Square Error3T
R-Squared0.50
Significance0
Slope377,966
Total Sum of Squares79.6T

PAVmed Cost Of Revenue History

20246.7 M
20236.4 M
20223.6 M
2021585 K
202023 K

About PAVmed Series Financial Statements

PAVmed Series investors use historical fundamental indicators, such as PAVmed Series' Cost Of Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in PAVmed Series. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue6.4 M6.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for PAVmed Stock Analysis

When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.